GlassScriptPhysician profile
Corey L Diamond
NPI 1811983398
$7,724.85
in general payments reported to CMS, 2019-2025
44 companies · $549 in 2025
The $549 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,125 · 2020: $813 · 2021: $651 · 2022: $1,009 · 2023: $967 · 2024: $610 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $990.75 | 2019-2025 | |
| Glaxosmithkline, LLC. | $843.88 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $759.86 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $684.26 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $647.19 | 2019-2023 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $446.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $399.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $370.73 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $301.01 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.43 | 2019-2024 | Ofev |
| Sanofi-Aventis U.S. LLC | $252.00 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.42 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $222.32 | 2019-2022 | |
| Lilly USA, LLC | $216.28 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Teva Pharmaceuticals USA, INC. | $168.35 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.